Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to help us learn if an experimental imaging device called Diffuse Optical Spectroscopic Imaging (DOSI) can monitor tumor shrinkage during chemotherapy treatment and can predict if the tumor will respond to chemotherapy before the end of the treatment. This study will also help us understand the biological reason for how DOSI works.


Clinical Trial Description

There is considerable interest in developing imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy (NAC), which is chemotherapy given before surgical removal of the tumor, both prior to and as early as possible during the course of treatment. The efficacy and practicality of conventional imaging approaches in the NAC setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging (DOSI) is an experimental imaging method that allows patients to be followed before and during treatment with a cost-effective, bedside, handheld scanning probe. DOSI is a non-invasive technology developed at the University of California, Irvine Beckman Laser Institute. Studies will be performed at seven clinical sites on approximately 200 suspected breast cancer patients, of which 150 are expected to undergo neoadjuvant chemotherapy (NAC). As a primary aim, the investigators will evaluate whether DOSI can predict NAC pathologic complete response (pCR), which is defined as no tumor cell left in the resected tissue at surgery) by the mid-point of the therapy regimen. As non-invasive DOSI is obtained rapidly with no risk/discomfort, this experimental imaging modality could be used as an indicator of pathologic response which has been an established indicator of long-term survival. The investigators long-term goal is to provide oncologists with a relatively simple, risk-free bedside tool that can be used to help inform medical decisions on chemotherapy regimen, duration, and timing of surgery, thereby maximizing therapeutic response and minimizing unnecessary toxicity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02725658
Study type Interventional
Source University of California, Irvine
Contact
Status Withdrawn
Phase N/A
Start date December 2015
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05544123 - The Treatment Situation of Chinese County Population With Breast Cancer
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Active, not recruiting NCT01247480 - Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer N/A
Recruiting NCT04626986 - Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor N/A
Completed NCT04805775 - Desflurane and Postoperative Sleep Quality in Patients Undergoing Elective Breast Surgery N/A
Recruiting NCT03347864 - 68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients Early Phase 1
Completed NCT03684408 - Radiofrequency Chip for Localization of Non-Palpable Breast Lesions N/A
Recruiting NCT04692818 - 3D Ultrasound Breast Imaging N/A
Not yet recruiting NCT04825444 - Clinical Study of Vascular Imaging Evaluation of Computed Tomography Photoacoustic Breast Imaging System
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT02470819 - Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer N/A
Completed NCT00859261 - Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound N/A
Active, not recruiting NCT05169437 - Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors Phase 2
Recruiting NCT03870620 - Metastatic Breast Cancer in Austria
Completed NCT05185752 - Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery N/A
Recruiting NCT04852926 - Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.
Recruiting NCT06172270 - Sub-regional Tumor Segmentation Based on CEUS Perfusion Characteristics: Enhancing Breast Tumor Diagnosis
Recruiting NCT04948983 - The Effect of a Patient Decision Aids for Breast Cancer Screening N/A
Not yet recruiting NCT06251544 - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer Phase 1